These included hormone receptor status (p = 0.021), HER2 status (p = 0.007), tumor size (T stage, p = 0.058), clinical stage (stage II vs. III, p = 0.067), tumor grade (p = 0.062), dual anti-HER2 therapy (p = 0.02), and PNI (p = 0.038). Here, ERBB2 is linked to neoplasm.